TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Pimodivir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum Observed Plasma Concentration (Cmin) of Pimodivir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve From Time of Administration to 12 Hours After Dosing (AUC [0-12]) of Pimodivir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preliminary activity/efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Slope of EEG Theta Band Power Over Fentanyl Effect Site Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Slope of Minute Ventilation Index Over Theta Band Power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Slope of Response Time Over Minute Ventilation Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Reaction Time as a Function of Theta Power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean percent change in lesional QSM per year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent QSM change per year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Total Severity Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cooperation with rehabilitation
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in level of self-reported financial burden
Endpoint domain: Life impact
Endpoint subdomain: Societal/carer burden
Primary endpoint: Area under the plasma insulin concentration curve from 0 to 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Brain activity in stress-related networks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Brain gray matter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Brain cortical thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: NSE serum level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: U-turn time of realization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time from symptom onset to Oseltamivir access
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: change in Disease Activity Score (DAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of return of spontaneous circulation (ROSC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety of Dapivirine
Endpoint domain: Adverse events/effects
Primary endpoint: Score change from baseline on IGA at Week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resting cardiac end-diastolic volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cerebrovascular reactivity to CO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Maximum tolerated dose (MTD) as assessed by dose-limiting toxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SVR12 (Sustained Virologic Response at Week 12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Embryo quality at Day 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Embryo quality at Day 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Embryo quality at blastocyst stage (Day 5)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Embryo quality at blastocyst stage (Day 6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bacterial count (CFU/cm2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Absolute change in patient-reported anxiety scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sensory block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Identification of Maximum Tolerated Dose (MTD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pulmonary Function (Lung Function)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Quality of life and anxiety status
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Decrease in emergency department visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Implant revisions
Endpoint domain: Adverse events/effects
Primary endpoint: Reasons of revisions
Endpoint domain: Adverse events/effects
Primary endpoint: Night cough frequency score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance of Skye ActiveBarrier
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Controlled Hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Survival of the uterus 1 year after transplantation
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of participants responding to treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: treatment outcomes of mild cognitive impairment and dementia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Test IGA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility measured by recruitment number
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Decreased cerebral blood flow (CBF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Measure of vasoreactivity to CO2 (VRCO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Increase in cortical AB plaque burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: MACES at 12 months following PCI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Participant's Subjective discomfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time to comfortably open the eyes after the application of eyelid cleansing wipe
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urine Drug Test
Endpoint domain: Adverse events/effects
Primary endpoint: In-hospital Intubation/Mechanical Ventilation Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rate of potentially avoidable admissions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mu-opioid receptor binding potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Delay of recurrence of suicide attempt
Endpoint domain: Mortality/survival
Primary endpoint: Time to initiation of antiretroviral therapy (ART)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinician Administered PTSD Scale (CAPS-IV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Slope of the strength duration function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: S-concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: elimination half-time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body composition (percent body fat and fat-free mass)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasting Serum total cholesterol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cognition as Measured by RBANS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clearance of intraventricular blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achievement of LDL-cholesterol Goals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in expression of mononuclear cell genes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Hamilton depression rating scale (HDRS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: early detection of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Accuracy of SARS-CoV-2 antibody immunoassays
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infective exacerbation warning
Endpoint domain: Adverse events/effects
Primary endpoint: Peak TCD velocities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of elevated TCD velocities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalization of TCD velocities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cytomegalovirus infection/disease recurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Cognition measured by MCCB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Patient Experience Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Awakening Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Response (> 25% Reduction in T2 Flair)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subject Reported Quality of Life Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Recurrent appendicitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency and Severity of Observed Adverse Events, Grade 3 or Higher
Endpoint domain: Adverse events/effects
Primary endpoint: Assessment of facial swelling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of trismus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of soft tissue healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of bone healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CNS Objective Response Rate (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in total FGDI severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve (AUC) to time infinity of oxycodone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve (AUC) to last quantifiable concentration of oxycodone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of oxycodone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in chest radiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Patients in the SPIN Cohort Who Meet the Cut-off Thresholds for Eligibility
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of Patients Who Consent to Participation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Participant Grade on Usability of the SPIN-HAND Program Based on Post-trial Patient Interviews
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Accommodation changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change From Baseline in Diurnal IOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: score of SF-36
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Severity of Sepsis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: General impression scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Acyl ghrelin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Increased number of tumor antigen specific circulating T Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from baseline in mechanical pain sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Newborn Respiratory Distress Syndrome improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of new ischemic foci
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Navigation: completion of maze
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in HAM-D-17 Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Follow-up with Primary care physician
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence of Central Nervous System (CNS) Hemorrhagic Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Complete Pathological Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Rate of T-downstaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of patients with NIHSS ≤1 or a reduction of 4 or more points
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Subjects With Anti-pertussis Toxoid, Anti-filamentous Haemagglutinin, Anti-pertactin Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Thoracic Kyphosis Angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Low Back Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Back Postural Behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration of voriconazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Narcotic usage in morphine equivalents
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of Patients With Adverse Drug Reactions (ADRs)
Endpoint domain: Adverse events/effects
Primary endpoint: HbA1c (Glycated hemoglobin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Falls Efficacy Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Decrement of the pain on VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrement of the pain on NRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Experiencing Suicidal Ideation or Suicidal Behavior
Endpoint domain: Adverse events/effects
Primary endpoint: ileostomy time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Recurrence rate of renal stone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Self-Reported Pain With Movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported Pain With Walking (From Iowa Gait Test)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Visual Analogue Scale (VAS24) Score at Week 4
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change From Baseline in VAS24 Score at Week 52
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Protoporphyrin IX (PpIX) fluorescence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cooling plethysmography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nailfold capillary microscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase physical activity compliance long-term
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Lessen insulin resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction of brain damage biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Computerized Cognitive Assessments
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Functional Assessment of Cancer Therapy - Cognition (FACT COG)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Levels of soluble forms and ligands of RAGE in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Ocular comfort
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of anti-depressant prescriptions filled
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: EGFRi rash severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Need for oxytocin retreatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: QLQ-C30
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: QLQ-LC13
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Ki, measure of FDG uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative vomiting/nausea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self reported cigarette and smokeless tobacco use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vessel Wall Enhancement Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: 5 Times Sit to Stand (5xSTS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee Extensors Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in pruritic score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: ratio of secondary TB identified and started on treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Waist and hip circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Three Item Severity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: In vitro rates of adipocyte turnover
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: inotropic score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Creatine kinase MB level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: resumption of spontaneous rhythm after aortic cross clamp off
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Summed Pain Intensity Differences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time for fistula closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Clinical Global Impression-Effectiveness (CGI-E) Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Subjects With Treatment-Emergent Adverse Events (TEAEs) and Dose Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Symptom severity score of UFS-QOL
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Modes of consumption
Endpoint domain: General outcomes
Primary endpoint: Prevalence of staphylococcus aureus strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Subjects Reporting at Least One Treatment Emergent Adverse Event (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects Reporting at Least One Serious Treatment Emergent Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: number of appropriate ICD/CRT-D discharges
Endpoint domain: Mortality/survival
Primary endpoint: rate of presence of anti-SARS-CoV-2 antibodies (Ig G _ Ig M)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of patients with severe clinical deterioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: respiratory impedance parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: International Normalized Ratio (INR) on CoaguChek
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: International Normalized Ratio (INR) Performed by Hospital Laboratory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Diagnosis concordance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thyroid hormone equilibria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes